Outcome of Board Meeting held today i.e., Friday, 9th May, 2025 at Registered Office of the Company has inter alia considered and approved the following businesses : (1)Audited Financial ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.6 pts less than Nifty Microcap 250 and 0.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Adline Chem Lab Ltd met on May 9, 2025 and approved the audited financial results for Q4 and full year ended March 31, 2025. Total income for FY25 stood at Rs 24.89 lakhs compared to Rs 0.01 lakhs in FY24 (restated), with the company reporting a loss after tax of Rs 13.22 lakhs, an improvement from a Rs 27.18 lakh loss last year. The company remains in a weak financial position with negative other equity of Rs 733.95 lakhs, total borrowings of around Rs 284 lakhs, and negative operating cash flow of Rs 22.61 lakhs. The Board appointed M/s Rahul Doshi & Co as Internal Auditor for FY26 and M/s Jitendra Parmar & Associates as Secretarial Auditor for FY25, replacing M/s Jay Pandya and Associates. The resignation of Company Secretary Mrs. Ritu Singh (effective April 22, 2025) was also noted.
Shareholders should note the auditor's 'Other Matter' flag regarding material modifications in a related-party contract with Vivanza Lifescience Pvt Ltd (a group entity) done without prior shareholder approval, which is a governance red flag. Despite a smaller loss this year, the company continues to have negative net worth, heavy borrowings, and cash burn from operations, making it a high-risk, small-cap stock.